Adverum Biotechnologies, Inc. Increase Decrease In Operating Lease Liability
Adverum Biotechnologies, Inc. reported Increase Decrease In Operating Lease Liability of $668.00 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2025-11-12
- Adverum Biotechnologies, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was $1.13M, a 18.99% increase year-over-year.
- Adverum Biotechnologies, Inc. increase decrease in operating lease liability for the quarter ending 2025-06-30 was -$957.00K, a 221.91% decline year-over-year.
- Adverum Biotechnologies, Inc. increase decrease in operating lease liability for the quarter ending 2025-03-31 was $491.00K, a 32.09% decline year-over-year.
- Adverum Biotechnologies, Inc. increase decrease in operating lease liability for the quarter ending 2024-12-31 was -$4.88M.
- Adverum Biotechnologies, Inc. increase decrease in operating lease liability for fiscal 2024 was -$2.42M.
- Adverum Biotechnologies, Inc. increase decrease in operating lease liability for fiscal 2023 was -$3.22M, a 123.68% decline from fiscal 2022.
- Adverum Biotechnologies, Inc. increase decrease in operating lease liability for fiscal 2022 was $13.61M, a 364.72% increase from fiscal 2021.
- Adverum Biotechnologies, Inc. increase decrease in operating lease liability for fiscal 2021 was $2.93M.
| Period end | Increase Decrease In Operating Lease Liability 1 month | Increase Decrease In Operating Lease Liability 1 month as first filed | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|---|---|
| 2025-09-30 | $1.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $177.00K derived: sum of 2 quarters · filed 2025-11-12 | $668.00K 10-Q · filed 2025-11-12 | -$4.21M derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2025-06-30 | -$957.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$466.00K 10-Q · filed 2025-08-12 | -$5.34M derived: sum of 3 quarters · filed 2025-08-12 | -$4.39M derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2025-03-31 | $491.00K 10-Q · filed 2025-05-14 | -$4.39M derived: sum of 2 quarters · filed 2025-05-14 | -$3.44M derived: sum of 3 quarters · filed 2025-11-12 | -$2.65M derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2024-12-31 | -$4.88M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | -$3.93M derived: sum of 2 quarters · filed 2025-11-12 | -$3.14M derived: sum of 3 quarters · filed 2025-11-12 | -$2.42M 10-K · filed 2025-04-15 | ||
| 2024-09-30 | $953.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.74M derived: sum of 2 quarters · filed 2025-11-12 | $2.46M 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | $785.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $1.51M 10-Q · filed 2025-08-12 | ||||
| 2024-03-31 | $723.00K 10-Q · filed 2025-05-14 | |||||
| 2023-12-31 | -$3.22M 10-K · filed 2025-04-15 | |||||
| 2023-03-31 | -$7.90M 10-K · filed 2025-04-15 | -$8.30M 10-Q · filed 2023-05-11 | ||||
| 2022-12-31 | $13.61M 10-K · filed 2024-03-18 | |||||
| 2021-12-31 | $2.93M 10-K · filed 2023-03-30 | |||||
| 2020-12-31 | -$1.54M 10-K · filed 2022-03-29 |